Aspire-Lakewood Holdings, Inc.
ASBP Healthcare Biotechnology
Aspire-Lakewood Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6,200.00. In the quarter to June 2026, EPS grew 97.5%, free cash flow fell 85.5% and total debt fell 79.7%, each against the same quarter a year earlier.
Follow ASBP
Aspire-Lakewood Holdings, Inc. (ASBP) Altman Z-score
Aspire-Lakewood Holdings, Inc.'s Altman Z-score for fiscal 2025 is −83.47, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −83.47 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | (4.79) | — | −5.74 | |
| Retained earnings / total assets | (20.77) | — | −29.08 | |
| EBIT / total assets | (14.75) | — | −48.67 | |
| Market value of equity / total liabilities | 0.03 | — | 0.02 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Distress zone | −83.47 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −199.09 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ENSC Ensysce Biosciences, Inc. compare | −29.4× |
| PLUR Pluri Inc. compare | −30.4× |
| CASIF CASI Pharmaceuticals Inc. compare | −47.1× |
| ASBP Aspire-Lakewood Holdings, Inc. | −83.5× |
| ACTU Actuate Therapeutics, Inc. compare | — |
| CTXR Citius Pharmaceuticals, Inc. compare | — |
| AEON AEON Biopharma, Inc. compare | — |
| INAB IN8bio, Inc. compare | — |
| PASG Passage Bio, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets